Research
Hormonal
Multiple risk factors should be targeted simultaneously in T2DM patients to reduce CV events.
A comprehensive approach addressing multiple risk factors is essential for effective cardiovascular disease prevention in T2DM patients.
StrongSupportsmedium confidence
Multiple risk factors should be targeted simultaneously in such high-risk patients in order to efficiently reduce the risk of CV events.
Why this rating
The claim is supported by findings from randomized controlled trials.
Source
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Niki Katsiki et al. · Expert Opinion on Pharmacotherapy · 2017
DOI 10.1080/14656566.2017.1351946
reviewCited 42×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →